… patients have received focused ultrasound treatment for dyskinesia with Parkinson’s disease (PD), providing more … the Focused Ultrasound Foundation , that seeks to alleviate dyskinesia caused by long-term use of levodopa, a drug commonly used to treat PD. Dyskinesias are involuntary, uncontrollable movements …

… antagonism of mGluR5 attenuates L-DOPA-induced dyskinesia (LID) in a pre-clinical model of Parkinson´s … inhibit the gradual development and long-term priming for dyskinesia as induced by chronic treatment with L-DOPA de … but its utility is severely limited by the emergence of dyskinesia (abnormal involuntary movements) in the majority …

… much more control over her day—especially through her dyskinesia, the debilitating, uncontrollable movements that … for PD. Annette says she wasn’t the first to notice her dyskinesia; others realized she was moving before she did. … that I felt embarrassed, but I knew I looked funny.” The dyskinesia also causes her to drop things, and its …

… accepted for review the New Drug Application (NDA) for a dyskinesia therapy. Dyskinesia -- characterized by uncontrolled, involuntary … therapy specifically designed to target levodopa-induced dyskinesia. Developed by Adamas Pharmaceuticals, the drug is …

… benefit in a pre-clinical model of L-DOPA induced dyskinesia. If our nicotinic agonist demonstrates efficacy … but we currently lack direct evidence that it will improve dyskinesia in pre-clinical or clinical studies. The purpose … in a well validated pre-clinical model of levodopa induced dyskinesia, the ability of our nicotinic agonist to suppress …

… often diminishes over time, and side effects such as dyskinesia (involuntary movements) can become prevalent and … the center of the brain (pallidotomy) can often reduce the dyskinesia, yet typical procedures require surgery or a high … A total of 15 Parkinson’s patients with dyskinesia will be enrolled and treated, divided over three …